Related references
Note: Only part of the references are listed.Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer
Liang Mao et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia
Hui Sun et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10years
A. -S. Lang et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2015)
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
Lisa Christiansson et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Myeloid derived suppressor cells in chronic myeloid leukemia
Cesarina Giallongo et al.
FRONTIERS IN ONCOLOGY (2015)
Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy
Jean-Claude Chomel et al.
Oncotarget (2015)
CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs
Regina Jitschin et al.
BLOOD (2014)
Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients
Cesarina Giallongo et al.
PLOS ONE (2014)
Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse
Takayuki Yoshimoto et al.
ONCOIMMUNOLOGY (2014)
Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities
Cirino Botta et al.
FRONTIERS IN ONCOLOGY (2014)
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Susan Branford et al.
BLOOD (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation
Cesarina Giallongo et al.
BMC CANCER (2013)
The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients
Seiichiro Katagiri et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib
Izuru Mizoguchi et al.
CANCER SCIENCE (2013)
Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
Lisa Christiansson et al.
PLOS ONE (2013)
Association of an increased frequency of CD14+HLA-DRlo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL)
Michael P. Gustafson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Increased natural killer cells and decreased CD3+CD8+CD62L+T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib
Kazuma Ohyashiki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
On the armament and appearances of human myeloid-derived suppressor cells
Isabel Poschke et al.
CLINICAL IMMUNOLOGY (2012)
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
King Pan Ng et al.
NATURE MEDICINE (2012)
Quantitative and functional analyses of CD4+CD25+FoxP3+ regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate
Emmanuel Bachy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells
Cesarina Giallongo et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy
Peter Rohon et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Mechanism of T Cell Tolerance Induced by Myeloid-Derived Suppressor Cells
Srinivas Nagaraj et al.
JOURNAL OF IMMUNOLOGY (2010)
Role of extracellular membrane vesicles in the pathogenesis of various diseases, including cancer, renal diseases, atherosclerosis, and arthritis
H. Clarke Anderson et al.
LABORATORY INVESTIGATION (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Dasatinib inhibits the proliferation and function of CD4(+)CD25(+) regulatory T cells
Fei Fei et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Tumor-Derived Microvesicles Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes
Eva U. Wieckowski et al.
JOURNAL OF IMMUNOLOGY (2009)
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
S. Mustjoki et al.
LEUKEMIA (2009)
Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells
Heather G. Jorgensen et al.
BLOOD (2007)
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
Mhairi Copland et al.
BLOOD (2006)
The immunobiology of cancer immunosurveillance and immunoediting
GP Dunn et al.
IMMUNITY (2004)
Share Paper
